StockData
Danaher Corp logo

Danaher Corp

DHRNYSEIndustrial Instruments For Measurement, Display, and ControlFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 26, 2026Last filing: 10-Q on Jul 21, 2026Score 12/3027% above fair value
$227.97−4.26 (-1.83%)

Close on Nov 2, 2026Market cap $160.26BP/E 40.5Yield –

Danaher Biotechnology — North America by Quarter

Biotechnology — North America ($M)

Danaher Biotechnology — North America: $550M in Q3 2026, down 11.9% from a year earlier.

Latest, Q3 2026
550
Period ended Sep 30, 2026
Change on a year earlier
-11.9%
624 in Q3 2025
History
15 quarters
Since Q1 2023
Sources
10
Documents cited below

Where the Q3 2026 figure comes from

Source: Danaher SEC 10-Q (2026Q3, filed 2026-10-21) ↗

2-dimensional revenue breakdown in Revenue Disclosures (Note 3 / Note 6, continuing operations basis following the Veralto spin-off); Q4 is calculated as Full Year (10-K) minus 9-month (10-Q Q3).

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

Cite this data

StockData. (2026). Danaher Biotechnology — North America ($M), quarterly Q1 2023–Q3 2026 [Data set]. Compiled from Danaher SEC filings and investor materials. https://stockdatahq.com/stocks/dhr/kpis/disagg-biotech-geo-na

See every metric in the Danaher KPI table. Data updated Nov 2, 2026.